Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred revenue, net of current	$ 163,089	$ 185,722
AstraZeneca Agreements [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Revenue	175,326	$ 175,646
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred revenue, net of current	156,200
Deferred Revenue	175,300
Net unbilled co-development revenue	$ 19,100

Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Parenthetical) (Detail) - USD ($)
$ in Thousands

Mar. 31, 2023

Dec. 31, 2022

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Deferred revenue, net of current

$ 163,089

$ 185,722

AstraZeneca Agreements [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Deferred Revenue

175,326

$ 175,646

AstraZeneca Agreements [Member] | U.S./RoW [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Deferred revenue, net of current

156,200

Deferred Revenue

175,300

Net unbilled co-development revenue

$ 19,100